Federal appeals court bars generics for Otezla until 2028
A US appeals court has given Amgen more time to profit off its psoriasis and psoriatic arthritis blockbuster Otezla — with five more years until generics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
